Across TCGA pan-cancer cohorts, CLDN25 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CLDN25 data layer compared with 11 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CLDN25 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLDN25 expression acts as an unfavorable survival marker.

LUAD, UCEC, and SKCM are the cancer types where CLDN25 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.399	0.815	<.001	46	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	0.345	0.614	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CLDN25 tumor-vs-normal RNA expression · all CLDN25 data types